Yahoo Finance Conmed Corp (CNMD) Q1 2024 Earnings Call Transcript Highlights: Robust Growth and Strategic Insights
Total Sales: $312.3 million, up 5.7% year-over-year.
GAAP Net Income: $19.7 million, compared to $1.8 million in Q1 2023.
Adjusted Net Income: $24.8 million, up 20.3% year-over-year.
Adjusted EPS: $0.79, increased 19.7% year-over-year.
US Sales Growth: 7.2% increase.
International Sales Growth: 4.2% increase.
Worldwide Orthopedics Revenue: Grew 3.0%; US up 10.6%, International down 1.6%.
Worldwide General Surgery Revenue: Increased 8.2%; US up 5.7%, International up 14.1%.
Adjusted Gross Margin: 55.6%, up 160 basis points from prior year.
Research and Development Expense: 4.4% of sales.
Adjusted SG&A Expenses: 38.7% of sales.
Interest Expense: $8.2 million.
Adjusted Effective Tax Rate: 23.8%.
Cash Balance: $33.9 million at quarter end.
Long-term Debt: $990.1 million at quarter end.
Operational Cash Flow: $29.1 million, significantly improved from -$3.8 million in Q1 2023.
Capital Expenditures: $2.0 million, down from $4.3 million in Q1 2023.
Full Year Revenue Guidance: Adjusted to $1.33 billion to $1.355 billion due to currency impacts.
Adjusted EPS Guidance for the Year: Lowered by $0.05 to $4.25 to $4.35.
Release Date: April 24, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Q & A Highlights
Q: Can you discuss the competitive threats in general surgery and how they compare to your offerings like AirSeal? A: Curt Hartman, CEO, noted that it's still early to fully assess the competitive landscape. However, Conmed's AirSeal continues to hold a strong clinical position with proven benefits such as reduced surgery length and post-op pain. The company's guidance already accounts for potential competitive pressures.
Q: Are there more investments being made in the traditional laparoscopic side to counter potential competitive pressures? A: Curt Hartman, CEO, indicated that while specific investment details are confidential, Conmed is actively pursuing opportunities in both laparoscopic and robotic surgery, leveraging their existing capabilities and market presence.
Q: What are the expectations for BioBrace's performance in 2024, especially with its expansion into the foot and ankle market? A: Curt Hartman, CEO, expressed confidence in BioBrace, anticipating it to generate double-digit millions in revenue for 2024, bolstered by its new applications in foot and ankle treatments.
Q: How does the AirSeal system perform economically and in terms of reimbursement in ASCs compared to hospital settings? A: Curt Hartman, CEO, explained that while the ASC market is still developing for procedures like those using AirSeal, the system's clinical benefits facilitate its adoption without significant pricing pressures, regardless of the setting.
Q: Could you provide an update on the orthopedics and foot and ankle business, particularly regarding any supply chain challenges? A: Curt Hartman, CEO, acknowledged past supply issues but noted improvements and a positive growth trajectory. The recent appointment of a new general manager for the foot and ankle segment is expected to strengthen performance further.
Q: What is the impact of recent smoke evacuation legislation on the business, and how do you see it influencing future growth? A: Curt Hartman, CEO, remarked that while legislation adoption has been slower than expected, states with such laws show higher growth rates in related products. Conmed supports these legislative efforts, aligning with their commitment to safer surgical environments.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
This article first appeared on GuruFocus.
